GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Liabilities-to-Assets

Starton Therapeutics (Starton Therapeutics) Liabilities-to-Assets : 1.99 (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Starton Therapeutics's Total Liabilities for the quarter that ended in Jun. 2023 was $8.43 Mil. Starton Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $4.24 Mil. Therefore, Starton Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 1.99.


Starton Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Starton Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Liabilities-to-Assets Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
Liabilities-to-Assets
0.73 2.17 3.49

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
Liabilities-to-Assets Get a 7-Day Free Trial 2.17 - 3.45 3.49 1.99

Competitive Comparison of Starton Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Starton Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starton Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starton Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Starton Therapeutics's Liabilities-to-Assets falls into.



Starton Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Starton Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Liabilities-to-Assets (A: Mar. 2023 )=Total Liabilities/Total Assets
=7.456/2.137
=3.49

Starton Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 is calculated as

Liabilities-to-Assets (Q: Jun. 2023 )=Total Liabilities/Total Assets
=8.425/4.243
=1.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starton Therapeutics  (NAS:STA) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Starton Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Starton Therapeutics (Starton Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines